Pfizer Signs MOU With Wuhan To Establish First R&D Center In Midwest China; Ranks Number One In China

SHANGHAI - Pfizer is expanding its presence in central and Western China, having signed a memorandum of understanding with Wuhan National Bioindustry Base Construction and Management Office Nov. 25 to establish a new R&D site in the National Bioindustry Base Biolake in Wuhan, the province capital of Hubei

More from Archive

More from Scrip